The strong beat and raised guidance confirm the Health Care Benefits margin recovery thesis is on track. Monitor the Health Services and Pharmacy Consumer Wellness segments for continued pressure from pharmacy client price improvements and reimbursement headwinds. The raised FY guidance provides a clear catalyst for upward EPS revisions.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 6 $86.76entry
- T+1 · 6mo ago +0.58%α +0.91% · $87.26
- T+5 · 6mo ago +9.68%α +8.54% · $95.15
- T+20 · 6mo ago +5.32%α +2.54% · $91.37
- T+60 · 4mo ago +21.28%α +20.21% · $105.22
Price Chart
How similar events traded
Executive Summary
CVS Health reported strong Q1 2026 results with Adjusted EPS of $2.57, significantly beating the $2.21 consensus estimate, and raised full-year 2026 guidance across all key metrics. Total revenues grew 6.2% YoY to $100.4B, driven by a sharp improvement in the Health Care Benefits segment (MBR improved 270 bps to 84.6%). The company raised its FY2026 Adjusted EPS guidance range to $7.30-$7.50 from $7.00-$7.20, signaling confidence in margin recovery despite cautious commentary on macro headwinds.
Key Financial Metrics
Key Facts
- Q1 2026 Adjusted EPS of $2.57 vs consensus $2.21 (beat by +16.3%)
- Q1 2026 GAAP diluted EPS of $2.30 vs $1.41 YoY
- Total revenues $100.4B, up 6.2% YoY from $94.6B
- Health Care Benefits segment MBR improved to 84.6% from 87.3% YoY (-270 bps)
- Health Care Benefits adjusted operating income surged 52.6% to $3.04B
- FY2026 Adjusted EPS guidance raised to $7.30-$7.50 from $7.00-$7.20
- FY2026 GAAP diluted EPS guidance raised to $6.24-$6.44 from $5.94-$6.14
- FY2026 cash flow from operations guidance raised to at least $9.5B from at least $9.0B
- Operating income increased 38.7% to $4.68B, driven by absence of prior-year litigation charges and segment improvement
- Health Services segment adjusted operating income declined 7.1% YoY to $1.49B
- Pharmacy Consumer Wellness segment adjusted operating income declined 8.8% YoY to $1.20B
Financial Impact
Q1 Adjusted EPS beat consensus by $0.36 (+16.3%); full-year guidance raised by $0.30 at midpoint
Risk Factors
- Health Services segment adjusted operating income declining 7.1% YoY signals ongoing PBM pricing pressure
- Pharmacy Consumer Wellness adjusted operating income down 8.8% YoY due to reimbursement pressure and seasonal illness weakness
- Management noted 'cautious view' on macro headwinds and elevated cost trends for remainder of 2026
- Medical membership declined ~600K sequentially due to individual exchange exit
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000064803-26-000051 |
| Document: cvs-20260506.htm | 0000064803-26-000051 |
| Document: 0000064803-26-000051-index-headers.html | 0000064803-26-000051 |
| Document: 0000064803-26-000051-index.html | 0000064803-26-000051 |
| Document: 0000064803-26-000051.txt | 0000064803-26-000051 |
| 8-K Data (Synthetic) | 0000064803-26-000051 |
Track record
25 reports on CVS
3 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +32.33% at T+60 after the Apr 8, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 13, 20264d ago Court Ruling Neutral 3/10 No price data
- Nov 6, 202610d ago Insider Buy Bullish 4/10 Entry $85.25 Now $88.59 +3.92% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 6/10 Entry $79.96 Now $88.59 +10.79% settles Dec 3
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $79.96 Now $88.59 +10.79% settles Dec 3
- Oct 26, 202621d ago Institutional Cluster Neutral 3/10 Entry $92.53 Now $88.59 −4.26% settles Nov 23
- Oct 15, 20264w ago Press Release Neutral 2/10 Entry $92.58 to $89.79 Now $88.59 −4.31% ▼ −3.01% −1.11% vs SPY
- Sep 30, 20266w ago Press Release Neutral 2/10 Entry $85.20 to $90.33 Now $88.59 +3.98% ▲ +6.02% +5.32% vs SPY
- Aug 5, 202614w ago 8-K Bullish 8/10 Entry $99.12 to $97.23 Now $88.59 −10.62% ▼ −1.91% −1.31% vs SPY
- Jul 10, 202618w ago Press Release Neutral 2/10 Entry $104.15 to $95.46 Now $88.59 −14.94% ▼ −8.35% −10.77% vs SPY
- Jun 29, 202620w ago Court Ruling Bullish 5/10 Entry $103.58 to $107.74 Now $88.59 −14.47% ▲ +4.02% +4.30% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers